TherapeuticsMD (TXMD) Notes Payables (2010 - 2022)

TherapeuticsMD's (TXMD) quarterly Notes Payables came in at $1.8 million in Q3 2022, up 1067.33% on a QoQ basis from $150000.0 in Q3 2012.

TherapeuticsMD (TXMD) Notes Payables (2010 - 2022) Analysis & Trends

TherapeuticsMD (TXMD) has 4 years of Notes Payables data on file, last reported at $1.8 million in Q3 2022.

Quarterly Notes Payables changed N/A year-over-year to $1.8 million in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $1.8 million (changed N/A YoY) and the FY2011 annual result came in at $200000.0, down 63.2% from the prior year.
Notes Payables rose to $1.8 million in Q3 2022, from $150000.0 in the prior quarter.
In the past five years, Notes Payables ranged from a high of $1.8 million in Q3 2022 to a low of $1.8 million in Q3 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-
10	TherapeuticsMD	23.54 Mn	14.35 Mn	-

Download Data